Dr. Kevin Francis Omeara, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 190 Arrowhead Dr, Evanston, WY 82930 Phone: 307-679-8391 Fax: 307-783-8299 |
Dr. Thomas Charles Laucomer, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 190 Arrowhead Drive, Evanston, WY 82930 Phone: 307-789-3636 |
Dr. Nathan C Schafer, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: Wyoming State Hospital, Highway 150 South, Evanston, WY 82930 Phone: 307-789-3464 |
Marion Cathryn Bishop, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 190 Arrowhead Dr, Evanston Regional Hospital, Evanston, WY 82930 Phone: 307-789-3636 |
News Archive
Pacira Pharmaceuticals, Inc. today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery.
IRIN examines how the WHO's recent declaration that the MenAfriVac meningitis A vaccine can be transported or stored for up to four days without refrigeration will affect immunization campaigns in Africa's meningitis belt, which runs from Senegal to Ethiopia.
Children whose parents provide them with learning materials like books and toys and engage them in learning activities and meaningful conversations in infancy and toddlerhood are likely to develop early cognitive skills that can cascade into later academic success, finds a new study by NYU's Steinhardt School of Culture, Education, and Human Development.
Patients with a low-grade type of brain tumor called glioma who received radiation therapy plus a chemotherapy regimen, including procarbazine, lomustine and vincristine (PCV), experienced a longer progression-free survival and overall survival than patients who received radiation therapy alone, according to the results of the clinical trial, Radiation Therapy Oncology Group 9802 published in the April 7 issue of the New England Journal of Medicine.
KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has secured an initial funding round of $2.5 million from four investors – three biotechnology venture capital groups and one angel investor. The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test designed to identify risks to pregnancy ranging from pre-term birth to genetic conditions.
› Verified 2 days ago